Condition: Von Hippel Lindau · Von Hippel Lindau Disease · Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma · Sponsor: José Claudio Casali da Rocha
The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients with von Hippel-Lindau (VHL) syndrome.
This description comes directly from the study's public registry record.
José Claudio Casali da Rocha, Head of Oncogenetics · +55 41 98505 8585 · casali.rocha@accamargo.org.br
José Reinaldo De Oliveira Junior · +55 31 99549 3678 · j.junior@accamargo.org.br
Always discuss trial participation with your own doctor first.
| AC Camargo Cancer Center | São Paulo, São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07167329